What OFEV Treats: Main Uses and Benefits

This medication is generally considered relevant in conditions requiring a disease-modifying approach for chronic lung issues. It is applied across therapeutic domains including Idiopathic Pulmonary Fibrosis (IPF), Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and other chronic fibrosing interstitial lung diseases (ILDs) that demonstrate an actively worsening, or progressive, phenotype. The medication may be applied in situations involving these conditions where the scarring of the lung tissue actively worsens over time in both adults and in children/adolescents (age 6 and older).

“The therapy is commonly used to help with managing the progression of chronic lung scarring, which supports the patient during symptomatic phases.”

Core Benefit: Managing Functional Decline

It plays a role in managing the rate of decline in lung function, which is the physiological process that leads to increased symptoms. This therapeutic action contributes to easing the symptom load, and the treatment assists with maintaining functional stability related to lung volume, relevant for managing symptoms like increasing shortness of breath and chronic cough. This intervention supports general well-being during symptomatic phases, contributing to easing the overall symptom load related to lung capacity.

Quick Fact: Relief for Progressive Fibrosis
Therapeutic Focus	Plays a role in managing the rate of decline in lung function
Symptom Relevance	Contributes to easing the overall symptom load related to chronic cough and dyspnea
Use Context	Applied in conditions characterized by actively worsening lung scarring
Supportive Focus	May be part of symptomatic management in situations where patients experience episodes associated with acute respiratory exacerbations (in IPF)

Regulatory References

1. European Medicines Agency therapeutic overview

Eligibility Map: Who can and cannot use OFEV — Official Regulatory Information

The eligibility for OFEV (nintedanib) is strictly defined by regulatory bodies based on specific patient conditions and populations. The following tables summarize who is and is not permitted to use this medicine according to official regulatory documentation.

Contraindicated Populations	Eligibility Status
Pregnancy	Contraindicated (Can cause fetal harm)
Hypersensitivity	Contraindicated (Known allergy to nintedanib, peanut, soya, or excipients)

Condition/Population Limitations	Eligibility Status
Moderate or Severe Hepatic Impairment (Child-Pugh B or C)	Not Recommended (Safety and efficacy not studied)
Mild Hepatic Impairment (Child-Pugh A)	Restricted Use (Allowed, but a reduced starting dose is required)
Severe Renal Impairment/End-Stage Renal Disease (ESRD)	Not Established (Safety and efficacy not studied)
Females of Reproductive Potential	Conditional Use (Mandatory use of highly effective contraception)
Lactation/Breastfeeding	Not Recommended (Potential for serious adverse reactions in infant)
Children under 6 years of age	Not Recommended (Safety and efficacy not established)

Eligibility is generally established for adults ( ge 18 years) and, for certain indications, may extend to adolescents ( ge 6 years) in some jurisdictions. These eligibility constraints are primarily focused on physiological states that critically affect the drug's safety profile or on populations where sufficient efficacy data are absent.

OFEV (nintedanib) interacts with other medicines and products due to its metabolic and transport pathways, necessitating specific management strategies as defined in official regulatory documents.

Documented Pharmacokinetic Interactions

OFEV is a substrate for the efflux transporter P-glycoprotein (P-gp) and, to a lesser extent, the metabolizing enzyme CYP3A4. Interactions are categorized based on their effect on nintedanib exposure:

• Potent P-gp and CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, St. John's Wort): Concomitant use with these agents is generally avoided because they can significantly decrease nintedanib exposure, potentially reducing effectiveness.
• Potent P-gp and CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin): These agents may increase nintedanib exposure. Patients require close monitoring for tolerability, and management of adverse reactions may involve a temporary interruption or dose reduction.

Other Clinically Significant Interactions

• Anticoagulants (e.g., Warfarin): OFEV may increase the risk of bleeding. Patients receiving full anticoagulation therapy must be closely monitored for signs of bleeding, and adjustments to the anticoagulant regimen may be necessary.
• Corticosteroids and Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Concomitant use is associated with an increased risk of gastrointestinal perforation. Caution is advised, and OFEV must be discontinued if perforation develops.

Molecular Targeting: Inhibition of Growth Factor Receptors

OFEV's core mechanism involves the competitive inhibition of specific Receptor Tyrosine Kinases (RTKs), primarily the Platelet-Derived Growth Factor Receptor (PDGFR) and the Fibroblast Growth Factor Receptor (FGFR) families. By binding to the ATP pocket inside the cell, the active ingredient Nintedanib blocks the energy source required for receptor activation, thereby disrupting the profibrotic signaling cascade at its earliest molecular step.

---

Cellular Effect: Suppressing Myofibroblast Activity

The inhibition of PDGFR and FGFR signaling suppresses the downstream messages that drive cellular growth and transformation. This action specifically limits the proliferation and differentiation of fibroblasts into active, scar-forming myofibroblasts. This results in a pharmacological modulation of the cell type responsible for pathological tissue deposition.

---

Physiological Consequence: Limiting Tissue Remodeling

By reducing the activity and number of myofibroblasts, the mechanism slows the rate of synthesis and accumulation of Extracellular Matrix (ECM) components, such as collagen. This fundamental physiological change limits the progression of structural stiffening and scarring of the tissue, maintaining the existing organ architecture over time.

How to Use OFEV: Official Administration Guidelines

OFEV (nintedanib) is structured as a long-term, oral therapy based on standardized protocols. Its use is defined by a strict administration schedule, precise dosage, and specific rules for intake conditions.

---

Administration Scope

Feature	Instruction
Route of administration	The method of use is the oral route, utilizing soft capsules.
Standard Dosing Schedule	The standard starting and maintenance dose for adults is 150 mg taken twice daily (BID).
Dose Management	The regimen may be reduced to 100 mg twice daily to manage tolerability, and the maximum total daily dose must not exceed 300 mg.
Timing in relation to meals	The capsule must be taken with food.
Missed-Dose Rule	If a dose is missed, patients should not take an extra capsule to compensate, but must resume at the next regularly scheduled time.
Special Procedural Conditions	The soft capsule must be swallowed whole with liquid; it must not be chewed, crushed, or opened.

---

Population-Specific Use Rules

While no adjustment is generally required for mild to moderate renal impairment, specific guidance applies to hepatic function. For individuals with mild liver (hepatic) impairment (Child-Pugh A), the recommended starting dose is 100 mg taken twice daily. Use is generally not recommended for those with moderate or severe impairment.

---

Resulting Procedural Structure

The procedural structure defines a continuous, twice-daily oral use pattern. To ensure proper administration, the standard sequence requires taking the prescribed 150 mg capsule with food, maintaining the capsule integrity (do not crush), and adhering strictly to the BID frequency. These official instructions define the standardized framework for consistent administration of the medicine.

Research evidence / Overview of studies for OFEV

---

Evidence for use in Idiopathic Pulmonary Fibrosis (IPF)

The evidence base for OFEV in adults with Idiopathic Pulmonary Fibrosis (IPF) primarily comes from two large, short-term randomized controlled trials (RCTs), along with their pooled data. These studies focused on a specific functional measure: the annual rate of change in lung function, measured by Forced Vital Capacity (FVC). Research also explored secondary functional measures, such as the time elapsed before the first acute worsening (exacerbation) of the disease or mortality related to the respiratory condition.

The findings from these trials describe patterns related to the main functional measure. Studies reported observations regarding the annual rate of FVC change between the observed populations receiving the medicine and the placebo groups, across the 52-week duration. However, follow-up durations were limited relative to the progressive nature of IPF, and data for individuals with very advanced disease were not the focus of the main trials.

---

Evidence for use in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Research exploring OFEV for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) is largely structured around one pivotal 52-week randomized controlled trial. This study tracked the annual rate of FVC change over the study interval in adults with relatively recent systemic disease diagnosis. The studies reported measurements suggesting patterns related to the annual rate of FVC change between the studied group and the placebo group.

Evidence for use in Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Evidence for chronic Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) is derived from a single 52-week RCT which examined a diverse group of patients whose conditions demonstrated a predefined worsening pattern. Studies monitored how functional measures evolved, and the central trial reported measurements indicating patterns related to the annual rate of FVC change between the two main groups. Due to the trial design, the population included many different underlying diagnoses grouped together, and long-term data for this diverse group remains limited.

---

Evidence in Children and Adolescents (Pediatric PF-ILDs)

For children and adolescents (age 6 to 17 years) with progressive fibrosing ILDs, research primarily focused on studies to understand how the medicine is absorbed and processed by the body (pharmacokinetics) to support regulatory review. Functional outcomes were tracked but were considered exploratory, not primary, study goals. Data are sparse, and certainty regarding functional patterns is limited.

Common questions about OFEV (FAQ)

Q: Is OFEV approved for children and adolescents?

According to official regulatory documents, nintedanib is approved in some jurisdictions for children and adolescents aged 6 to 17 years old. It is specifically indicated for treating clinically significant progressive fibrosing interstitial lung diseases (PF-ILDs) and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in this age group.

Q: What should I do if I’m taking blood thinners (anticoagulants) with OFEV?

Regulatory information indicates that nintedanib may increase a person's risk of bleeding, particularly when used with blood thinners like anticoagulants. If full anticoagulation therapy is being used, close monitoring for bleeding is necessary. Any necessary adjustments to the anticoagulant treatment should be discussed with a healthcare provider.

Q: What is the rationale for reducing the dose from 150 mg to 100 mg?

Official product information states that a reduction from the standard dosage regimen is available to help manage side effects. The dose regimen may be reduced to 100 mg twice daily by a healthcare provider to manage common adverse reactions, such as diarrhea, if they become intolerable.

Q: Does OFEV have a documented interaction with St. John’s Wort?

Yes, official product information states that the concomitant use of OFEV and St. John's Wort should be avoided. St. John's Wort is classified as a potent inducer, which means it can significantly speed up the clearance of nintedanib from the body. This interaction may decrease the concentration of the drug in the blood, potentially reducing its overall effectiveness.

Q: What is the average duration of treatment with OFEV?

Nintedanib is designed as a long-term, continuous oral therapy intended to slow the progression of chronic fibrotic diseases. While clinical trials supporting its approval typically evaluated effectiveness over a 52-week period, the medicine is generally taken for an extended duration based on the condition being treated.

Q: Which medical professional (doctor/specialist) typically prescribes OFEV?

Official information states that treatment with nintedanib is typically initiated by a doctor experienced in the diagnosis and treatment of the specific conditions for which the medicine is indicated. This often involves specialists such as pulmonologists or rheumatologists.

Q: How long after stopping OFEV will it take for the drug to be completely cleared from my body?

Official pharmacokinetic studies indicate that nintedanib is eliminated from the body relatively quickly. The effective half-life of the drug in patients is approximately 9.5 hours, and the terminal half-life is estimated to be between 10 to 15 hours.

Q: What specific dietary or supplement restrictions are necessary while taking OFEV (besides St. John's Wort)?

The medication is administered with food, as specified in the administration guidelines. Some authoritative sources note that grapefruit juice and Seville orange juice can increase the concentration of nintedanib in the blood, and their consumption is often discouraged. It is also noted that alcohol may potentially worsen certain adverse reactions, such as diarrhea or liver-related side effects.

How to Store and Dispose of OFEV (Nintedanib)

OFEV capsules require storage at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. To ensure product stability, the medication must be kept protected from moisture and stored in its original container or packaging.

Protection and Handling

It is a mandatory storage requirement to keep OFEV out of the sight and reach of children. If the contents of a capsule are accidentally handled, the hands must be washed immediately and thoroughly.

Disposal Requirements

Unused or expired OFEV must not be disposed of in household trash or poured into wastewater. The capsules must be returned to a pharmacist or collected via local programs for disposal according to official pharmaceutical waste regulations.